Safety and Efficacy Study of OMS721 in Patients With Atypical Hemolytic Uremic Syndrome
Study sponsor: Omeros Corporation
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2021-02-02Actual
Enrollment · participants6Actual
Source updated2025-12-10Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.